| Sponsored by |
| The International Society for Antiviral Research |
| Le Centre Sheraton Hotel |
| Montreal, Quebec, Canada |
| April 13–17, 2008 |
| Table of Contents | |
| Page | |
| Organization and Conference Committees | A3 |
| Organizing Secretariats, The International Society for Antiviral Research | A4 |
| Corporate Sponsors | A5 |
| Keynote Address, Social Functions | A6 |
| Scientific Program | A7 |
| Sunday, April 13, 2008 | A8 |
| Keynote Address | A8 |
| Monday, April 14, 2008 | A8 |
| Oral Session I: Mini-Symposium: Novel Targets for HIV Therapy | A8 |
| Oral Session II: Respiratory and Emerging Viruses | A8 |
| Poster Session I: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods | A12 |
| Tuesday, April 15, 2008 | A9 |
| Oral Session III: Hepatitis Viruses | A9 |
| Clinical Symposium: Clinical Update on Antiviral Drugs | A10 |
| Poster Session II: Herpesviruses, Topical Microbicides, Poxviruses, Other Antiviral Agents, Medicinal Chemistry, and Animal Models | A15 |
| Wednesday, April 16, 2008 | A10 |
| Oral Session IV: Retroviruses | A10 |
| Oral Session V: Herpesviruses and Poxviruses | A10 |
| Shotgun Poster Session | A11 |
| Thursday, April 17, 2008 | A11 |
| Oral Session VI: Other Viruses, Veterinary Viruses, and Late Breaker Presentations | A11 |
| Abstracts | A18 |
| Complete Author Index | A69 |
| Invitation to the 22nd International Conference on Antiviral Research | A75 |
| Locations for Future International Conferences on Antiviral Research | A76 |
| Organization |
| International Society for Antiviral Research |
| and |
| Twenty-First International Conference on Antiviral Research |
| Officers |
| President—Christopher McGuigan, Cardiff, Wales, UK |
| President-Elect—Amy K. Patick, San Diego, CA, USA |
| Secretary—Joseph M. Colacino, South Plainfield, NJ, USA |
| Treasurer—Dale L. Barnard, Logan, UT, USA |
| Past President—John A. Secrist III, Birmingham, AL, USA |
| ISAR Conference and Program Committees |
| Conference Chair: John A. Secrist III, Birmingham, AL, USA |
| Program Chair: Robert W. Buckheit Jr., Frederick, MD, USA |
| Karen K. Biron, Research Triangle Park, NC, USA |
| Erik De Clercq, Leuven, Belgium |
| John C. Drach, Ann Arbor, MI, USA |
| José A. Esté, Barcelona, Spain |
| Chris McGuigan, Cardiff, Wales, UK |
| Charles E. McKenna, Los Angeles, CA, USA |
| Chris Meier, Heidelberg, Germany |
| Amy K. Patick, San Diego, CA, USA |
| Leroy B. Townsend, Sedona, AZ, USA |
| Donald Smee, Logan, UT, USA |
| Organizing Secretariats | |
| Courtesy Associates | John A. Secrist III |
| 2025 M Street, NW | Southern Research Institute |
| Suite 800 | P.O. Box 55305 |
| Washington, DC 20036 | Birmingham, AL 35255-5305 |
| USA | USA |
| Phone: +1 202 973 8690 | Phone: +1 205 581 2442 |
| Fax: +1 202 331 0111 | Fax: +1 205 581 2870 |
| E-mail: isar@courtesyassoc.com | E-mail: Secrist@sri.org |
| The International Society for Antiviral Research (ISAR) |
The Society was organized in 1987 as a non-profit scientific organization for the purpose of advancing and disseminating knowledge in all areas of antiviral research. To achieve this objective, the Society organizes an annual meeting. The Society is now in its 21st year of existence, and has approximately 450 members representing 30 countries. For membership application forms or further information, please contact Dr. Joseph M. Colacino, Secretary, ISAR; Vice President, Drug Discovery, PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ 07080, phone: +1 908 222 7000x131; fax: +1 908 222 0567; E-mail: jcolacino@ptcbio.com. Membership application forms will also be available at the Conference Registration desk, or from our website www.isar-icar.com.
| Platinum |
| Gilead Sciences Inc., Foster City, CA, USA |
| Gold |
| Pfizer, Inc., New York, NY, USA |
| Silver |
| Boehringer Ingelheim (Canada) Ltd., Laval, Quebec, Canada |
| Glaxo Smith Kline, Middlesex, United Kingdom |
| Bronze |
| Abbott Laboratories, Abbott Park, IL, USA |
| Biota Holdings, Melbourne, Victoria, Australia |
| Debiopharm Group, Lausanne, Switzerland |
| Elsevier, Amsterdam, The Netherlands |
| Pharmasset, Inc., Princeton, NJ, USA |
| PTC Therapeutics, Inc., South Plainfield, NJ, USA |
| Southern Research Institute, Birmingham, AL, USA |
| Idenix Pharmaceuticals, Cambridge, MA, USA |
| Additional Support Provided by: |
| Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA |
| KEYNOTE ADDRESS |
| “The Next Decade of Antiviral Chemotherapy” |
| Mark Wainberg, Ph.D. |
| Sunday, April 13, 2008 |
| 5:00–6:00 p.m. |
| Salle de bal ouest |
| Le Centre Sheraton Hotel |
| MINI-SYMPOSIA | |
| “Novel Targets for HIV Therapy” | “Clinical Update on Antiviral Drugs” |
| Monday, April 14, 2008 | Tuesday, April 15, 2008 |
| 8:00 a.m.–12:00 p.m. | 1:00–4:00 p.m. |
| Salle de bal ouest | Salle de bal ouest |
| Le Centre Sheraton Hotel | Le Centre Sheraton Hotel |
| SOCIAL EVENTS |
| Opening Reception |
| with light hors d’oeuvres |
| Sunday, April 13, 2008 |
| 6:00–8:00 p.m. |
| Salon Drummond |
| Le Centre Sheraton Hotel |
| Conference Banquet |
| Wednesday, April 16, 2008 |
| Reception | Dinner and Program |
| 7:30 p.m. | 8:00–10:00 p.m. |
| Foyer Sal de bal | Sal de bal ouest |
| Le Centre Sheraton Hotel | Le Centre Sheraton Hotel |
| Final Program |
| Twenty-First International Conference on Antiviral Research |
| Sponsored by the |
| International Society for Antiviral Research |
Le Centre Sheraton HotelMontreal, Quebec, Canada
| April 13–17, 2008 |
| 2008 International Conference on Antiviral Research | ||
| Sunday, April 13, 2008 | ||
| Opening Greetings | ||
| Salle de bal ouest | ||
| 16:45 | Welcome to the 21st ICAR, Christopher McGuigan, Ph.D., President, ISAR | |
| 16:50 | Welcome to Montreal, John A. Secrist III, Ph.D., Chair, ICAR Conference Committee | |
| 16:55 | Introduction of the Keynote Speaker, Amy Patick, Ph.D., President-Elect, ISAR | |
| Keynote Address | ||
| Salle de bal ouest | ||
| 17:00 | Keynote Address Speaker: Mark Wainberg, Ph.D., McGill University, Montreal, Quebec, Canada “The Next Decade of Antiviral Chemotherapy” | |
| Monday, April 14, 2008 | ||
| Oral Session 1: Mini-Symposium: Novel Targets for HIV Therapy | ||
| Chairs: Tomas Cihlar, Ph.D. and Jose Este, Ph.D. | ||
| Salle de bal ouest | ||
| 08:00 a.m.–12:00 p.m. | ||
| 08:00 | 1. | APOBEC 3G: Innate Defense Against Retroviruses and Retroelements |
| Warner Greene, M.D. | ||
| Gladstone Institute of Virology and Immunology, San Francisco, CA, USA | ||
| 08:30 | 2. | LEDGF/P75 as a Co-factor of HIV-1 Integrase and as a New Antiviral Target |
| Zeger Debyser, M.D., Ph.D. | ||
| IRC, KULAK and KULeuven, Leuven, Belgium | ||
| 09:00 | 3. | Trim 5 Alpha-mediated Late Restriction on HIV-1 Production |
| Yasuhiro Ikeda, Ph.D. | ||
| Mayo College of Medicine, Rochester, MN, USA | ||
| 09:30 | Break | |
| 10:00 | 4. | Assembly of the Immature and Mature Viral Structure as Potential Antiviral Target |
| Hans-Georg Krausslich, M.D. | ||
| University of Heidelberg, Heidelberg, Germany | ||
| 10:30 | 5. | Late Stages of the HIV-1 Replication Cycle as Targets for Novel Antiviral Agents |
| Eric Freed, Ph.D. | ||
| HIV Drug Resistance Program, National Cancer Institute, Frederick, MD, USA | ||
| 11:00 | 6. | The Role of Vpu Protein in HIV-1 Pathogenesis |
| Edward Stephens, Ph.D. | ||
| University of Kansas Medical Center, Kansas City, KS, USA | ||
| 11:30 | Panel Discussion | |
| Elion Award Lecture | ||
| Salle de bal ouest | ||
| 13:15 | Presentation of Award: Christopher McGuigan, Ph.D., President ISAR Awardee Lecture: Jan Balzarini, Ph.D., Rega Institute for Medical Research, Leuven, Belgium “The Potential of Carbohydrate Binding Agents as Novel Therapeutics to Treat Enveloped Virus Infections” | |
| Oral Session 2: Respiratory and Emerging Viruses | ||
| Chairs: Colleen Jonsson, Ph.D. and Simon Tucker, Ph.D. | ||
| Salle de bal ouest | ||
| 02:00–04:00 p.m. | ||
| 14:00 | 7. | Peptide-based Entry Inhibitors for Influenza |
| Thomas Voss1, Christopher LeBlanc1, Joseph Barbercheck1, Bryan Kaplan1, Russell Wilson2, Garry Robert1 | ||
| 1Tulane School of Medicine, New Orleans, LA, USA; 2Autoimmune Technologies, LLC, New Orleans, LA, USA | ||
| 14:15 | 8. | Factors Affecting Susceptibility of H5N1 Influenza Viruses to Neuraminidase Inhibitor Oseltamivir |
| Elena Govorkova1, Natalia Ilyushina1, Jennifer McClaren1, Tri Naipospos2, Neziha Yilmas3, Bounlom Douangngeun4, Robert Webster1 | ||
| 1St. Jude Children's Research Hospital, Memphis, TN, USA; 2Indonesia National Committee on Avian Flu Control and Pandemic Influenza Preparedness, Jakarta, Indonesia; 3Virology and NIC of Turkey Refik Saydam Hygiene Institute, Ankara, Turkey; 4National Animal Health Centre, Vientiane, Laos | ||
| 14:30 | 9. | In Vivo Synergistic Combination Effect of Rimantadine and Oseltamivir Against Influenza A(H3N2) is Manifested in Several Dose Ratios |
| Lora Simeonova, Angel S. Galabov, Galina Gegova | ||
| The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | ||
| 14:45 | 10. | Development of Novel Selective Parainfluenza Virus Hemagglutinin–Neuraminidase Inhibitors |
| Irina V. Alymova1, Makiko Watanabe1, Vasiliy P. Mishin1, Y. Sudhakara Babu2, Allen Portner1 | ||
| 1Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA; 2BioCryst Pharmaceutical, Inc., Birmingham, AL, USA | ||
| 15:00 | 11. | Evaluation of Interferon Inducers, Ribavirin and Mouse Hyperimmune Serum in a Pathogenesis/Lethal Mouse Model Using a Mouse-adapted SARS-CoV |
| Dale Barnard1, Craig Day1, Miles Wandersee1, Yohichi Kumaki1, Andres Salazar2 | ||
| 1Utah State University, Logan, UT, USA; 2Oncovir, Inc., Washington DC, DC, USA | ||
| 15:15 | 12. | Therapies and Mechanisms of West Nile Virus Encephalitis and Neurological Sequelae |
| John D. Morrey1, Venkatraman Sidharthan1, Hong Wang1, Neil Motter1, Jeffery O. Hall1, Robert D. Skinner2 | ||
| 1Institute Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, USA; 2Center for Translational Neuroscience and Department of Neurobiology and Developmental Sciences, University of Arkansas Medical Sciences, Little Rock, AR, USA | ||
| Tuesday, April 15, 2008 | ||
| Oral Session 3: Hepatitis Viruses | ||
| Chairs: Phillip Furman, Ph.D. and Todd Parsley, Ph.D. | ||
| Salle de bal ouest | ||
| 08:00–11:30 a.m. | ||
| 08:00 | 13. | Plenary: HCV Culture System and Antiviral Development |
| Takaji Wakita | ||
| Director, National Institute of Infectious Diseases, Tokyo, Japan | ||
| 08:30 | 14. | Identification of Halosalicylamide Derivatives as a Novel Class of Allosteric Inhibitors of HCV NS5B Polymerase |
| Yaya Liu, Pamela Donner, Wen Jiang, Teresa Ng, Vijaya Gracias, Steve Baumeister, Paul Wiedeman, Linda Traphagen, Usha Warrior, Clarence Maring, Warren Kati, Stevan Djuric, Akhteruzzaman Molla | ||
| Antiviral Research, Abbott Laboratories, Abbott Park, IL, USA | ||
| 08:45 | 15. | Anti-Hepatitis C Virus Replicon Activity of Alkoxyalkyl Esters of (S)-HPMPA and Other Acyclic Nucleoside Phosphonates |
| David L. Wyles1, Robert T. Schooley1, Kelly A. Kaihara1, James R. Beadle1,2, Karl Y. Hostetler1,2 | ||
| 1Division of Infectious Disease, University of California, San Diego, La Jolla, CA, USA; 2Veterans Medical Research Foundation, San Diego, CA, USA | ||
| 09:00 | 16. | Discovery of a Novel HCV Helicase Inhibitor by a De Novo Drug Design Approach |
| Andrea Brancale1, Dimitrios Vlachakis1, Sahar Kandil1, Sonia Biondaro1, Colin Berry2, Johan Neyts3 | ||
| 1The Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; 2School of Bioscience, Cardiff University, Cardiff, United Kingdom; 3Rega Institute for Medical Research, KULeuven, Leuven, Belgium | ||
| 09:15 | Break | |
| 09:45 | 17. | PG 301029 Inhibits HCV Replication Through a Novel Late Stage Mechanism of Action |
| Todd B. Parsley, Lu Yang, Robert W. Buckheit Jr. | ||
| ImQuest BioSciences, Inc., Frederick, MD, USA | ||
| 10:00 | 18. | Different Incorporation Efficiencies for Nucleotide Analogs During HCV Polymerase RNA Synthesis Initiation and Elongation Phases |
| Han Ma1, Nicole Inocencio1, Vincent Leveque1, Genadiy Kalayanov2, David Smith1, Nick Cammack1, Nils Gunnar Johansson2, Klaus Klumpp1 | ||
| 1Roche, Palo Alto, CA, USA; 2Medivir AB, Huddinge, Sweden | ||
| 10:15 | 19. | HCV RNA Helicase Requirement for NS3 Oligomerization is Substrate-dependent: Characterization of RNA Substrates with Different Double Strand Lengths and RNA Binding-dependent Inhibition |
| Julie Hang, Yanli Yang, Vincent Leveque, Tony Giannetti, George Stepan, Nick Cammack, Klaus Klumpp | ||
| Roche, Palo Alto, CA, USA | ||
| 10:30 | 20. | Evaluation of MK-7009, A Novel Macrocyclic Inhibitor of NS3/4A Protease, in the Chimpanzee Model of Chronic Hepatitis C Virus Infection |
| S. Ludmerer, D. Graham, L. Handt, C. Fandozzi, C. Burlein, N. Liverton, J. McCauley, J. Vacca, D. Hazuda, S. Carroll, D. Olsen | ||
| Merck Research Labs, West Point, PA, USA | ||
| 10:45 | 21. | Novel Five-membered Ring Imino Sugar Derivatives Inhibit Flaviviruses via Distinct Mechanisms |
| Jinhong Chang1, Lijuan Wang1, Dongling Ma1, Robert Moriarty3, Benjamin Davis4, Peter Mason5, Baohua Gu1, Xiaodong Xu6, Ju-Tao Guo1, Timothy Block1,2 | ||
| 1Drexel University College of Medicine, Doylestown, PA, USA; 2Hepatitis B Foundation, Doylestown, PA, USA; 3University of Illinois, Chicago, IL, USA; 4University of Oxford, Oxford, United Kingdom; 5University of Texas Medical Branch, Galveston, TX, USA; 6Pharmabridge Inc., Doylestown, PA, USA | ||
| 11:00 | 22. | A Novel and Selective Inhibitor of Hepatitis B Virus Surface Antigen Secretion |
| Anne Marie Dougherty1, Haitao Guo2, Gael Westby1, Yuanjie Liu2, Ju-Tao Guo2, Anand S. Mehta2, Pamela Norton2, Baohua Gu2, Timothy M. Block1,2, Andrea Cuconati1 | ||
| 1Institute for Hepatitis and Virus Research, Doylestown, PA, USA; 2Drexel Institute for Biotechnology and Virology Research, Doylestown, PA, USA | ||
| 11:15 | 23. | Preclinical Development of the Amphipathic DNA Polymer REP 9AC for the Treatment of Hepatitis B Virus Infection |
| Faseeha Noordeen1, Andrew Vaillant2, Jean-Marc Juteau2, Allison Jilbert1,3 | ||
| 1School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, Australia; 2REPLICor Inc., Laval, QC, Canada; 3Infectious Diseases Laboratories, Institute of Medical and Veterinary Science, Adelaide, Australia | ||
| Clinical Symposium: Clinical Update on Antiviral Drugs |
| Chairs: Richard Pollard, Ph.D. and Ann Kwong, Ph.D. |
| Salle de bal ouest |
| 01:00–04:00 p.m. |
| Wednesday, April 16, 2008 | |
| Prusoff Young Investigator Award Lecture | |
| Salle de bal ouest | |
| 08:00 | Presentation of Award: Christopher McGuigan, Ph.D., President ISAR Awardee Lecture: Bruno Canard, Ph.D., Marseille, France “The Structure and Mechanism of RNA Virus Replication Enzymes: Endless Challenges for Drug Design” |
| Oral Session 4: Retroviruses | ||
| Chairs: Eric Freed, Ph.D. and Andrea Brancale, Ph.D. | ||
| Salle de bal ouest | ||
| 08:45–11:30 a.m. | ||
| 08:45 | 24. | Characterization of a Novel Series of gp120 Inhibitors |
| Tanya Parkinson, Peter Stephenson, Chris Pickford, Thien Duc Tran, David Williams, David Fenwick, Juin Fok-Seang, Iain Gardner, Mike Westby, Don Middleton, Manos Perros | ||
| Pfizer Global R&D, Sandwich, United Kingdom | ||
| 09:00 | 25. | Novel Mechanism of Action of Pyrimidinediones Yields Enhanced Sensitivity to Multi-Drug Resistant Virus Strains |
| Robert W. Buckheit Jr., Lu Yang, Tracy L. Hartman, Karen M. Watson | ||
| ImQuest BioSciences, Inc., Frederick, MD, USA | ||
| 09:15 | 26. | Development of the Dual Acting Pyrimidinedione IQP0528 as a Vaginal Topical Anti-HIV Microbicide |
| Karen M. Watson, Lu Yang, Christa E. Buckheit, Robert W. Buckheit Jr. | ||
| ImQuest BioSciences, Inc., Frederick, MD, USA | ||
| 09:30 | Break | |
| 09:50 | Invitation to the 22nd ICAR, Miami Beach, FL, USA, John A. Secrist III, Ph.D. | |
| 10:00 | ISAR Business Meeting | |
| 10:15 | 27. | Enzyme-triggered CycloSal-Pronucleotides |
| Chris Meier1, Henning Jessen1, Nicolas Gisch1, Jan Balzarini2 | ||
| 1Institute of Organic Chemistry, University of Hamburg, Faculty of Science, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany; 2Rega Institute for Medical Research, Catholic University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium | ||
| 10:30 | 28. | Peptide-based Inhibitors of HIV-1 RT Dimerization and Pol-polyprotein Maturation |
| Pascal Clayette1, Audrey Agopian2, Nathalie Dereuddre-Bosquet1, Chritine Goffinet3, Rahima Yousfi1, Jérome Depollier2, Karen Storck1, Eric Gros2, Oliver Keppler3, Gilles Divita2 | ||
| 1Neurovirology Department, SPI-BIO, Fontenay aux Roses, France; 2CRBM, CNRS, Montpellier, France; 3Virology Department, University of Heidelberg, Heidelberg, Germany | ||
| 10:45 | 29. | Low In Vitro Potential for Class-specific Toxicity of GS-9148, A Novel Nucleotide Reverse Transcriptase Inhibitor |
| Genevieve Laflamme1, Constantin Boojamra1, Lijun Zhang1, Hon Hui1, Robyn Fisher2, Richard Mackman1, Adrian Ray1, Tomas Cihlar1 | ||
| 1Gilead Sciences, Foster City, CA, USA; 2Vitron, Tucson, AZ, USA | ||
| 11:00 | 30. | Pth15: An Interfacial Inhibitor of HIV-1 Integrase That Efficiently Blocks HIV-1 Replication |
| Edwige Gros1, Edwire Guiot1, Audrey Agopian1, Eric Deprez2, Jean Francois Mouscadet2, Myriam Witvrouw3, Gilles Divita1 | ||
| 1UMR 5237 CNRS CRBM, Montpellier, France; 2LBPA-CNRS UMR 8113, Cachan, France; 3LMVD University of Leuven, Leuven, Belgium | ||
| 11:15 | 31. | Effective Small Interfering RNAs Targeting Alpha V Integrin Inhibit HIV-1 Replication |
| Eduardo Pauls1, Ester Ballana1, Imma Clotet-Codina1, Berta Bosch1, Françoise Perron-Sierra2, Gordon Tucker2, Bonaventura Clotet1, Jose Esté1 | ||
| 1Retrovirology Laboratory IrsiCaixa, Badalona, Spain; 2Institut de Recherches Servier, Croissy sur Seine, France | ||
| Oral Session 5: Herpesvirsues and Poxviruses | ||
| Chairs: Rhonda Cardin, Ph.D. and Daniel Streblow, Ph.D. | ||
| Salle de bal ouest | ||
| 01:30–04:15 p.m. | ||
| 13:30 | 32. | Plenary: Role of Angiogenesis and Wound Repair Factors in the Acceleration of Allograft Rejection by Cytomegalovirus |
| Daniel Streblow | ||
| Oregon Health and Science University, Beaverton, OR, USA | ||
| 14:00 | 33. | Design, Synthesis and Evaluation of Novel Anti-VZV BCNAs |
| Christopher McGuigan1, Marco Migliore1, Geoffrey Henson2, Joseph Patti2, Graciela Andrei3, Robert Snoeck3, Jan Balzarini3 | ||
| 1Cardiff University, Cardiff, United Kingdom; 2Inhibitex, Alpharetta, GA, USA; 3Rega Institute, Leuven, Belgium | ||
| 14:15 | 34. | Maribavir Inhibits the Replication of Human Herpesvirus 6 and the Activity of the U69 Protein Kinase |
| Mark Prichard, Shannon Daily, Amie Perry, Earl Kern | ||
| University of Alabama School of Medicine, Birmingham, AL, USA | ||
| 14:30 | 35. | Antiviral Potency of ST-246 on the Production of Enveloped Orthopoxviruses and Characterization of ST-246 Resistant Vaccinia, Cowpox and Camelpox Viruses |
| Sophie Duraffour1,2, Solenne Vigne2, Aude Gracel2, Robert Jordan3, Dennis E. Hruby3, Jean-Marc Crance2, Daniel Garin2, Graciela Andrei1, Robert Snoeck1 | ||
| 1Rega Institute, Leuven, Belgium; 2CRSSA, Grenoble, France; 3SIGA Technologies, Inc., Corvallis, OR, USA | ||
| 14:45 | 36. | Vaccinia DNA Polymerase is Profoundly Inhibited by Cidofovir and (S)-HPMPA Incorporated into the Template Strand |
| Wendy Magee1, Karl Hostetler2, David Evans1 | ||
| 1University of Alberta, Edmonton, AB, Canada; 2University of California, San Diego, CA, USA | ||
| 15:00 | 37. | Development of a Model for the Study of Antivirals Against Molluscum Contagiosum Virus (MCV) |
| Graciela Andrei1, Joos Van den Oord2, Rita De Vos2, Sophie Duraffour1, Arlette Blondeel3, Thiery Simonart4, Erik De Clercq1, Robert Snoeck1 | ||
| 1Rega Institute, Leuven, Belgium; 2Pathology Department, UZ Leuven, Leuven, Belgium; 3Dermatology Department, Saint Pierre Hospital, Brussels, Belgium; 4Dermatology Department, Erasmus Hospital, Brussels, Belgium | ||
| 15:15 | 38. | In Vitro and In Vivo Efficacy of a Pyrimidine Nucleoside Analog Against Vaccinia and Cowpox Viruses |
| Debra Quenelle1, Mark Prichard1, Kathy Keith1, Deborah Collins1, Terri Rice1, John Secrist2, Kamal Tiwari2, Joseph Maddry2, Earl Kern1 | ||
| 1The University of Alabama, School of Medicine, Birmingham, AL, USA; 2Southern Research Institute, Birmingham, AL, USA | ||
| 15:30 | 39. | Effect of Treatment with the Cidofovir Analogue HDP-CDV in Guinea Pig Models of Cytomegalovirus Infection |
| Fernando Bravo1, Rhonda Cardin1, Karl Hostetler2, David Bernstein1 | ||
| 1Cincinnati Children's Hospital Medical Center, University of Cincinnati, Division of Infectious Diseases, Cincinnati, OH, USA; 2Division of Infectious Diseases, University of California, San Diego, La Jolla, CA, USA | ||
| 15:45 | 40. | A Single Accelerating Dose Study to Evaluate Safety and Pharmacokinetics (PK) of FV-100 in Healthy Subjects |
| S.M. Canas1, B. Wargin2, B. Boehlecke3, G. Henson4, J.M. Patti4, A.M. Morris4 | ||
| 1Prism Research, St. Paul, MN, USA; 2PK-PM Associates, Chapel Hill, NC, USA; 3Rho, Inc., Chapel Hill, NC, USA; 4Inhibitex, Inc., Alpharetta, GA, USA | ||
| 16:00 | 41. | Single-Dose Safety and Pharmacokinetics of ST-246, A Novel Orthopoxvirus Egress Inhibitor |
| Robert Jordan1, Kevin Jones1, Tove’ Bolken1, Deborah Tien1, Josef Strasser2, Shanthakumar T.R.1, Annie Frimm3, Michael Corrado3, Phoebe Strome3, Dennis Hruby1 | ||
| 1SIGA Technologies, Corvallis, OR, USA; 2TranTech Pharma, High Point, NC, USA; 3INC Research, Inc., Raleigh, NC, USA | ||
| Shotgun Poster Session |
| Chairs: Joseph Colacino, Ph.D. and Mark Prichard, Ph.D. |
| Salle de bal ouest |
| 04:15–06:15 p.m. |
| Thursday, April 17, 2008 | ||
| Oral Session 6: Other Viruses, Veterinary Viruses, and Late Breaker Presentations | ||
| Chairs: David Rock, DVM and Justin Julander, Ph.D. | ||
| Salle de bal ouest | ||
| 09:00–11:30 a.m. | ||
| 08:00 | 42. | Plenary: Use of Antivirals for Control of High Consequence Animal Diseases |
| Daniel L. Rock | ||
| University of Illinois at Urbana-Champaign, Urbana, IL, USA | ||
| 08:30 | 43. | Design, Synthesis and Evaluation of 3-Ethynyl-Azole Nucleosides with Antiviral Activity Against Hantaviruses |
| Jeffrey Arterburn1, Sidath Kumarapperuma1, Marjan Jeselnik1, Dong-Hoon Chung2, Yangie Sun2, Willaim Parker2, Yong Kyu Chu2, Colleen Jonsson2 | ||
| 1New Mexico State University, Las Cruces, NM, USA; 2Southern Research Institute, Birmingham, AL, USA | ||
| 08:45 | 44. | A Derivate of the Antibiotic Doxorubicin Inhibits Dengue and Yellow Fever Virus Replication In Vitro |
| Suzanne Kaptein1, Michael Jacobs2, Andrea Gamarnik3, Erik De Clercq1, Ferenc Sztaricskai4, Johan Neyts1 | ||
| 1Rega Institute, Leuven, Belgium; 2Royal Free and University College Medical School, London, United Kingdom; 3Fundacion Instituto Leloir, Buenos Aires, Argentina; 4University of Debrecen, Debrecen, Hungary | ||
| 09:00 | 45. | One-third of the Surface of the Adenovirus Proteinase Contains Potential Drug Targets via a New Paradigm for Virion Maturation |
| Walter Mangel | ||
| Brookhaven National Laboratory, Upton, NY, USA | ||
| 09:15 | Break | |
| 09:45 | 46. | Efficacy of T-1106 or T-705, Alone or in Combination with Ribavirin, in the Treatment of Hamsters Infected with Yellow Fever Virus |
| Justin Julander1, Kristiina Shafer1, Don Smee1, John Morrey1, Yousuke Furuta2 | ||
| 1Institute for Antiviral Research, Utah State University, Logan, UT, USA; 2Toyama Chemical Co. Ltd., Tokyo, Japan | ||
| 10:00 | Late Breaker Presentation | |
| 10:15 | Late Breaker Presentation | |
| 10:30 | Late Breaker Presentation | |
| 10:45 | Late Breaker Presentation | |
| 11:00 | Late Breaker Presentation | |
| 11:15 | Late Breaker Presentation | |
| Monday, April 14, 2008 | ||
| Poster Session I: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods | ||
| Salle de bal centre et est | ||
| 47. | AlphaV Integrin-mediated Adhesion of Monocyte-derived Macrophages Influences HIV Infection | |
| Ester Ballana1, Eduardo Pauls1, Imma Clotet-Codina1, Berta Bosch1, Françoise Perron-Sierra2, Gordon Tucker2, Bonaventura Clotet1, Jose Esté1 | ||
| 1Retrovirology Laboratory IrsiCaixa, Badalona, Spain; 2Institut de Recherches Servier, Croissy sur Seine, France | ||
| 48. | Use of the HCV Cell Culture (HCVcc) System for Antiviral Drug Testing | |
| Jodi Beattie, Jacob Simmons, Amine Noueiry, Paul Olivo | ||
| Apath LLC, St. Louis, MO, USA | ||
| 49. | In Vitro Vascular Leak as a Model of Viral Hemorrhagic Fever | |
| Rebecca Brocato, Voss Thomas | ||
| Tulane School of Medicine, New Orleans, LA, USA | ||
| 50. | Resistance to Pyrimidinedione HIV Inhibitors Requires Multiple Mutations in Reverse Transcriptase, Envelope and Core Proteins | |
| Robert W. Buckheit Jr., Christa E. Buckheit, Robert W. Buckheit III, Karen M. Watson | ||
| ImQuest BioSciences, Inc., Frederick, MD, USA | ||
| 51. | Azaindole-based HIV-1 Integrase Specific Inhibitors Display Potent Anti-Retroviral Activity | |
| Scott Butler1, Michael Plewe2, Atsuo Kuki2, Teddy Johnson2, Qinghai Peng2, Dorothy Delisle2, Joanne Graham2, Hua Wu2, Amy Patick2 | ||
| 1Pfizer Global R&D, Sandwich Labs, Sandwich, United Kingdom; 2Pfizer Global R&D, La Jolla Labs, La Jolla, CA, USA | ||
| 52. | Establishment of a Cell-based HTS System for Discovery of Anti-Flavivirus Drugs | |
| Yali Chen, Chris Harver, Travis Warren, Dennis Hruby, Robert Jordan | ||
| SIGA Technologies, Corvallis, OR, USA | ||
| 53. | Mevastatin Markedly Potentiates the Anti-HCV Activity of Selective Inhibitors of HCV Replication and Delays or Prevents the Emergence of Antiviral Resistance | |
| Leen Delang, Johan Neyts | ||
| Rega Institute for Medical Research, KULeuven, B-3000 Leuven, Belgium | ||
| 54. | Comparative Virtual and Experimental Medium Throughput Screening for Hepatitis C Virus Polymerase Inhibitors | |
| Helene Dutartre1, Cecile Bussetta1, Stephane Betzi2, Joelle Boretto-Soler1, Claire Debarnot1, Mohamed Ben-Rahou1, Jean-Louis Romette1, Jean Claude Guillemot1, Karine Alvarez1, Xavier Morelli2, Bruno Canard1 | ||
| 1Department of Virology, AFMB-CNRS Universite d’Aix-Marseille, Marseille, France; 2CNRS-IBSM BIP laboratory, Marseille, France | ||
| 55. | MIV-170, A Novel NNRTI Exhibiting Tight Binding to HIV-1 Reverse Transcriptase (RT) | |
| Malin Elinder1, Helena Danielson1, Torsten Unge2, Guido VanHam3, Bo Öberg4 | ||
| 1Department of Biochemistry and Organic Chemistry, BMC, Uppsala University, Uppsala, Sweden; 2Department of Cell and Molecular Biology, BMC, Uppsala University, Uppsala, Sweden; 3Department of Microbiology, Institute of Tropical Medicine, Antwerpen, Belgium; 4Medivir AB, Huddinge, Sweden | ||
| 56. | Inverse Wavelet Transform in Virus–Cell Interaction Imaging | |
| Andriy Fedchuk1, Iryna Bartsykovska1, Alla Fedchuk2, Oleksandr Fedchuk1 | ||
| 1I.I. Mecnikov Odessa National University, Odessa, Ukraine; 2I.I. Mechnikov Ukrainian Anti-Plague Research Institute, Odessa, Ukraine | ||
| 57. | New Microscopic Description of Herpes Virus-Cell Dynamic System | |
| Oleksandr Fedchuk1, Alla Fedchuk2, Iryna Bartsykovska1, Andriy Fedchuk1 | ||
| 1I.I. Mechnikov Odessa National University, Odessa, Ukraine; 2I.I. Mechnikov Ukrainian Research Anti-Plague Institute, Odessa, Ukraine | ||
| 58. | Dielectric Spectroscopy as a Tool for Virus–Cell Interaction Rate Description | |
| Oleksandr Fedchuk1, Andriy Fedchuk1, Iryna Bartsykovska1, Alla Fedchuk2 | ||
| 1I.I. Mechnikov Odessa National University, Odessa, Ukraine; 2I.I. Mechnikov Ukrainian Anti-Plague Research Institute, Odessa, Ukraine | ||
| 59. | Placental and Monocyte-derived Macrophages have Different Secretome | |
| Katia Garcia1, Vivian Garcia1, Juliana Perez1, Fenghai Duan2, Loyda Melendez1 | ||
| 1University of Puerto Rico-Medical Sciences Campus, San Juan, PR, Puerto Rico; 2University of Nebraska Medical Center, Omaha, NE, USA | ||
| 60. | Inhibition of Human Rhinovirus Replication by Some Antivirals | |
| Irina Georgieva, Angel S. Galabov | ||
| The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | ||
| 61. | Broad Anti-Infective Activity of Viracea, An Echinacea-derived Product | |
| Tracy L. Hartman1, Karen M. Watson1, Lu Yang1, Meryl J. Squires2, Robert W. Buckheit Jr.1 | ||
| 1ImQuest BioSciences, Inc., Frederick, MD, USA; 2Merix Pharmaceutical Corporation, Barrington, IL, USA | ||
| 62. | Serine Palmitoyltransferase Inhibitor Suppresses HCV Replication in a Mouse Model | |
| Yuichi Hirata1, Takuya Umehara1, Masayuki Sudoh2, Fumihiko Yasui1, Michinori Kohara1 | ||
| 1Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; 2Kamakura Research Laboratories, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan | ||
| 63. | New Synthetic Histone Deacetylase Inhibitors CGMC0005 and CGMC0006 Effectively Reactivate Latently Infected Human Immunodeficiency Virus Type-1 (HIV-1) from ACH2 and J1.1 CD4+ T Cells | |
| Kee-Jong Hong, Sung-Soon Kim, Hak Sung Lee, Joo-Shil Lee, Byeong-Sun Choi | ||
| Korea Institute of Health, Seoul, Republic of Korea | ||
| 64. | Optimization of shRNA Features for Targeting Hepatitis C Virus | |
| Brian Johnston1, Alexander Vlassov3, Brent Korba2, Kristine Farrar2, Sampa Mukerjee2, Attila Seyhan4, Heini Ilves1, Roger Kaspar5, Devin Leake6, Sergei Kazakov1, Qing Ge1 | ||
| 1Somagenics Inc., Santa Cruz, CA, USA; 2Georgetown University Medical Center, Rockville, MD, USA; 3Ambion, Austin, TX, USA; 4Open Biosystems, Huntsville, AL, USA; 5Transderm Inc., Santa Cruz, CA, USA; 6Thermo Fisher Scientific, Lafayette, CO, USA | ||
| 65. | Anti-Influenza A Virus Inhibitory Effect of (−)-Epigallocatechin-3-O-Gallate Fatty Acid Monoester Derivatives | |
| Kunihiro Kaihatsu, Shuichi Mori, Nobuo Kato | ||
| Osaka University, Osaka, Japan | ||
| 66. | Computational Studies of gp41 6-Helix Bundle: Do Stabilized Energy of HIV Membrane Fusion Inhibitor C34 and Interaction Energy of gp41 6-Helix Bundle have Good Correlation with their Inhibitory Activity? | |
| Norihito Kawashita1,2, Yu-Shi Tian1, Masashi Yasuda1, U. Chandimal de Silva2, Rie Kashiwada3, Shota Nakamura2, Naohisa Goto3, Rika Nishikiori4, Kousuke Okamoto1, Masanori Kameoka2, Teruo Yasunaga2,3, Masaya Kawase2,4, Kazuyoshi Ikuta2,5, Tatsuya Takagi1,2,3 | ||
| 1Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan; 2Research Collaboration Center on Emerging and Re-emerging Infections, established by Research Institute for Microbial Diseases, Osaka University, and National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand; 3Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan; 4Department of Pharmacy, Osaka Ohtani University, Tondabayashi, Osaka, Japan; 5Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan | ||
| 67. | Synthesis of Structural Analogues of dUY11, a Potent Rigid Amphipathic Fusion Inhibitor Nucleoside | |
| Stanislav Khramyshev, Olga Valueva, Vladimir Korshun, Alexey Ustinov | ||
| Shamyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia | ||
| 68. | Chemically Synthesized Tunicamycin Derivatives Effectively Inhibit the Propagation of Classical Swine Fever Virus—A Surrogate Model for Hepatitis C Virus | |
| Ewelina Krol1, Boguslaw Szewczyk1, Ilona Wandzik2, Grzegorz Grynkiewicz3, Wieslaw Szeja2 | ||
| 1Department of Molecular Virology, University of Gdańsk, Gdańsk, Poland; 2Silesian Technical University, Gliwice, Poland; 3Pharmaceutical Institute, Warsaw, Poland | ||
| 69. | QSAR Analysis of Cytotoxicity in HeLa Cells | |
| V. Kuz’min1, A. Artemenko1, E. Muratov1, E. Varlamova1, V. Makarov2, O. Riabova2, P. Wutzler3, M. Schmidtke3 | ||
| 1A.V. Bogatsky Physical-Chemical Institute, Odessa, Ukraine; 2Research Center for Antibiotics, Moscow, Russia; 3Institute of Virology and Antiviral Therapy, Friedrich Schiller University, Jena, Germany | ||
| 70. | Peptide-based Entry Inhibitors for Paramyxoviruses | |
| Christopher LeBlanc1, Russell Wilson2, Peter Kulkosky2, Robert Garry1, Thomas Voss1 | ||
| 1Tulane School of Medicine, New Orleans, LA, USA; 2Autoimmune Technologies, LLC, New Orleans, LA, USA | ||
| 71. | Antiviral Effect of Ingenol and Gingerol During HIV-1 Replication in MT4 Human T Lymphocytes | |
| Hak Sung Lee, Sung-Soon Kim, Gab Jung Kim, Joo-Shil Lee, Eun-Jin Kim, Kee-Jong Hong | ||
| Korea Institute of Health, Seoul, Republic of Korea | ||
| 72. | Cystatin B Associates with STAT-1 in Monocyte Derived Macrophages and Placental Macrophages: A Possible Link to HIV Activation | |
| Claribel Luciano-Montalvo, Loyda Melendez-Guerrero | ||
| University of Puerto Rico, Medical Sciences Campus, San Juan, PR, USA | ||
| 73. | Use of AX-4 Cells for the Study of the Pharmacodynamics of Oseltamivir Carboxylate for Influenza Viruses in an In Vitro Hollow Fiber Infection Model System | |
| James McSharry, Qingmei Weng, Kate Soldani, Kris Zager, George Drusano | ||
| Ordway Research Institute, Albany, NY, USA | ||
| 74. | Sub-optimal Protease Inhibition of HIV-1: Effects on Virion Morphogenesis and RNA Maturation | |
| Michael D. Moore1, William Fu2, Roger G. Ptak2, Wei-Shau Hu1 | ||
| 1HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD, USA; 2Southern Research Institute, Frederick, MD, USA | ||
| 75. | Significance of 3b-dehydroxysterol-D24-reductase (DHCR24) in life cycle of Hepatitis C virus | |
| Tomohiro Nishimura1, Masaaki Sato1, Makoto Saito1, Yuri Kasama1, Michinori Kohara2, Kyoko Kohara1 | ||
| 1Kumamoto University, Kumamoto, Japan; 2RRINSHOKEN, Tokyo, Japan | ||
| 76. | Inhibition of Human T-Cell Lymphotropic Virus Type-1 Integrase by Dicaffeoylquinic Acids Extracted from Coffee (Coffea arabica) Seeds | |
| Ordonez Paula1, Panay Joel1, Cuesta-Astroz Yesid1, Ceballos Carolina1, Ceron Flavio1, Moncayo Alejandro2, Dominguez Martha C.1, Sanchez Adalberto1, Lareo Leonardo3, Garcia-Vallejo Felipe1 | ||
| 1Laboratory of Molecular Biology and Pathogenesis, Universidad del Valle, Cali, Columbia; 2Department of Chemistry, Universidad del Valle, Cali, Columbia; 3Laboratory of Computational and Structural Biochemistry and Bioinformatics, Pontificia Universidad Javeriana, Bogota, Columbia | ||
| 77. | Serine Side-Chain-linked Peptidomimetic Prodrugs of Cidofovir and Cyclic Cidofovir: C-Ester Effects on Transport and Activation | |
| Larryn W. Peterson1, Boris A. Kashemirov1, Ulrika Eriksson3, Jae-Seung Kim2, Stefanie Mitchell2, Paul Kijek2, Kyung-Dall Lee3, John M. Hilfinger2, Charles E. McKenna1 | ||
| 1Department of Chemistry, University of Southern California, Los Angeles, CA, USA; 2TSRL, Inc., Ann Arbor, MI, USA; 3Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA | ||
| 78. | Check of Antiviral Activity of Nanocomposites With Active Check of Antiviral Activity of Drugs Based on Nanocomposites, Which Contained Oligonucleotides for Direct Splitting Viral Genome of Influenza Virus Type A | |
| Dmitriy Pletnev1, Aleksei Evdokimov1, Evgeniy Belanov1, Ernst Malygin1, Sergey Balachnin1, Olga Serova1, Viktor Zinoviev1, Valentina Zarytova2, Asya Levina2, Marina Repkova2, Zinfer Ismagilov3, Nadegda Shikina3, Stanislav Zagrebelnyi4, Sergey Baiborodin5 | ||
| 1FSRI SRC VB “Vector”, Novosibirsk, Russia; 2Institute of Biochemistry and Fundamental Medicine SB RAS, Novosibirsk, Russia; 3Institute of Catalysis SB RAN, Novosibirsk, Russia; 4Novosibirsk State University, Novosibirsk, Russia; 5Institute of Citology SB RAN, Novosibirsk, Russia | ||
| 79. | NAC Reduces Apoptosis and Telomeres Shortening Subsequent to HIV-1 Exposure in an Astrocytoma Cell Line | |
| Michela Pollicita1, Carolina Muscoli2, Antonella Sgura3, Alberto Biasin3, Vincenzo Mollace2, Caterina Tanzarella3, Claudio Del Duca4, Paola Rodinò5, Carlo Federico Perno1, Stefano Aquaro1,6 | ||
| 1Department of Experiment Medicine and Biochemical Sciences, University Tor Vergata, Rome, Italy; 2Faculty Pharmacy, University Magna Graecia, Catanzaro, Italy; 3Department of Biology, University Roma3, Rome, Italy; 4Department of Biology, University Tor Vergata, Rome, Italy; 5Institute of Biology and Molecular Pathology, Rome, Italy; 6Department of Pharmaco-Biology, University of Calabria, Rende, Italy | ||
| 80. | A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-resistant Viruses | |
| Anneke Raney, Robert Hamatake, Wen Xu, Jean-Luc Girardet, Jean-Michel Vernier, Li-Tain Yeh, Barry Quart | ||
| Ardea Biosciences, Inc., Carlsbad, CA, USA | ||
| 81. | A Recombinant, Infectious Human Parainfluenza Virus Type 3 Expressing the Enhanced Green Fluorescent Protein for Use in High Throughput Antiviral Assays | |
| Jason P. Roth, Donald F. Smee, Dale L. Barnard | ||
| Utah State University, Logan, UT, USA | ||
| 82. | NGO Analysis of Impact of HIV Infection and Antiretroviral Therapies in Resource Poor Nations. Are We on Right Path to Control HIV? | |
| Pramod Sankapal1, Vaishali Sankapal2, Nirmal Rawandale3 | ||
| 1Health Alert Organization of India, [NGO], Dhule, India; 2Health Alert Organization of India, [NGO], Dhule, India; 3Health Alert Organization of India, [NGO], Dhule, India | ||
| 83. | A Cell-based High-throughput Screening Approach for the Discovery of New Inhibitors of the Influenza H5N1 Virus | |
| William Severson, Joseph Maddry, Xi Chen, Subramaniam Ananthan, Adrian Poffenberger, Lynn Rasumussen, Melinda Sosa, Lucile White, Diana Noah, Gary Piazza | ||
| Southern Research Molecular Libraries Screening Center, Birmingham, AL, USA | ||
| 84. | Influence of Hsp70 on HIV-1 Infection | |
| Ryuichi Sugiyama1, Yuichiro Habu2, Haruki Naganuma1, Hiroshi Takaku1,3 | ||
| 1Department of Life and Environmental Science, Chiba Institute of Technology, Chiba, Japan; 2Japanese Foundation for AIDS Prevention, Tokyo, Japan; 3High Technology Research Center, Chiba Institute of Technology, Chiba, Japan | ||
| 85. | Suppression of HCV RNA Replication by Baculovirus-mediated shRNA Expression Vectors | |
| Hitoshi Suzuki1, Nobushige Tamai1, Kunitada Shimotohno3, Yoshiharu Matsuura4, Hiroshi Takaku1,2 | ||
| 1Department of Life and Environmental Sciences, Chiba Institute of Technology, Narashino, Japan; 2High Technology Research Center, Chiba Institute of Technology, Narashino, Japan; 3Resaerch Institute, Chiba Institute of Technology, Narashino, Japan; 4Research Center for Emerging Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Japan | ||
| 86. | Synthesis and Evaluation of Octadecyloxyethyl Esters of Five 3-Hydroxy-2-(Phosphonomethoxy)Propyl Nucleoside Phosphonates in HIV-1 Infected Cells | |
| Nadejda Valiaeva1,2, Kathy A. Aldern1,2, Julissa Trahan1,2, James R. Beadle1,2, Karl Y. Hostetler1,2 | ||
| 1Division of Infectious Disease, University of California, San Diego, La Jolla, CA, USA; 2The Veterans Medical Research Foundation, San Diego, CA, USA | ||
| 87. | Dysregulation of the Antioxidant Enzyme Defense in Hispanic Women with HIV-associated Neurocognitive Disorder | |
| Ixane Velazquez1, Marines Plaud1, Juliana Perez-Laspiur1, Richard Skolasky2, Valerie Wojna1, Loyda Melendez1 | ||
| 1UPR-Medical Sciences Campus, San Juan, PR, USA; 2The John Hopkins University, Baltimore, MD, USA | ||
| 88. | Characterization of Small Molecule Inhibitors of West Nile Virus NS3 Serine Protease | |
| Prasanth Viswanathan1, Niklaus Mueller1, Nagarajan Pattabiraman2, Kyungae Lee3, Gregory Cuny3,4, Ratree Takhampunya11, Camilo Ansarah-Sabrino5, Theodore Pierson5, R. Padmanabhan1 | ||
| 1Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA; 2Department of Oncology, Georgetown University, Washington, DC, USA; 3New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Harvard Medical School, Boston, MA, USA; 4Laboratory for Drug Discovery in Neurodegeneration, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA; 5Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA | ||
| 89. | From RT Inhibitor to RT/IN Dual Inhibitor: An Rational Design | |
| Zhengqiang Wang, Robert Vince | ||
| Center for Drug Design, University of Minnesota, Minneapolis, MN, USA | ||
| 90. | Withdrawn | |
| 91. | Check of Antiviral Activity of Nanocomposites with Active Ligand Based on Model of Cattle's Diarrhea Virus (Model of Hepatitis C Virus) | |
| Viktor Zinoviev1, Aleksey Evdokimov1, Evgeniy Belanov1, Ernst Malygin1, Sergey Balachnin1, Olga Serova1, Dmitriy Pletnev1, Valentina Zarytova2, Asya Levina2, Marina Repkova2, Zinfer Ismagilov3, Nadegda Shikina3, Stanislav Zagrebelnyi4, Sergey Baiborodin5 | ||
| 1FSRI SRC VB “Vector”, Novosibirsk, Russia; 2Institute of Biochemistry and Fundamental Medicine SB RAS, Novosibirsk, Russia; 3Institute of Catalysis SB RAN, Novosibirsk, Russia; 4Novosibirsk State University, Novosibirsk, Russia; 5Institute of Citology SB RAN, Novosibirsk, Russia | ||
| 92. | MIV-170, a Novel NNRTI with Potent Activity Against HIV and HIV Mutants | |
| Bo Öberg, Britt Louise Sahlberg, Christer Sahlberg, Bertil Samuelsson, Kristina Wikström, Lotta Vrang, Hong Zhang | ||
| Medivir AB, Huddinge, Sweden | ||
| Tuesday, April 15, 2008 | ||
| Poster Session II: Herpesviruses, Topical Microbicides, Poxviruses, Other Antiviral Agents, Medicinal Chemistry, and Animal Models, | ||
| Salle de bal centre et est | ||
| 93. | Design and Synthesis of Novel Non-Nucleoside Anti-HCMV Agents | |
| R. Adak1, C. McGuigan1, R. Snoeck2, G. Andrei2, J. Balzarini2, E. Gorovits3, C. Chang3, B. Ames3, Y. Liu3, J. Vernachio3 | ||
| 1Cardiff University, Cardiff, United Kingdom; 2Rega Institute for Medical Research, Leuven, Belgium; 3Inhibitex Inc., Alpharetta, GA, USA | ||
| 94. | Susceptibility of Human Cytomegalovirus (HCMV) Drug-resistant Viruses to a New Class of Acyclic Nucleoside Phosphonate Analogues (ANPs) | |
| Graciela Andrei1, Pierre Fiten1, Marcela Krecmerova2, Antonín Holý2, Erik De Clercq1, Ghislain Opdenakker1, Robert Snoeck1 | ||
| 1Rega Institute, Leuven, Belgium; 2Gilead Sciences & IOCB Research Center, Academy of Sciences of the Czech Republic, Prague, Dominican Republic | ||
| 95. | Inhibition of HIV-1 Infection in Hu-PBL-SCID Reconstituted Mice by Rapamacyn | |
| Stefano Aquaro1,3, Caterina Lapenta2, Filippo Belardelli2, Carlo-Federico Perno3, Ferdinando Nicoletti4 | ||
| 1Department of Pharmaco-Biology, University of Calabria, Rende (CS), Italy; 2Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, Italy; 3Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Roma, Italy; 4Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Roma, Italy; 5Department of Biomedical Sciences, University of Catania, Catania, Italy | ||
| 96. | QSAR Analysis of Influence of Artifical Ribonucleases Structure on Their Anti-Influenza Activity | |
| A. Artemenko1, V. Kuz’min1, E. Muratov1, M. Kulinskiy1, V. Lozitsky2, A. Fedchuk2, T. Gridina2, L. Koroleva3, V. Silnikov3 | ||
| 1A.V. Bogatsky Physical-Chemical Institute, Odessa, Ukraine; 2Ukrainian Mechnikov Research Anti-Plague Institute, Odessa, Ukraine; 3Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia | ||
| 97. | Anti-Orthopoxviral Activity of the 2-Cycloalkylimino-5-(4-Nitrophenyl)-1,3,4-Thiadiazine Derivatives | |
| Evgeny Belanov1, Lyudmila Sidorova2, Vladimir Rusinov2, Nikolay Bormotov1, Sergey Balakhnin1, Olga Serova1, Valery Charushin2, Oleg Chupakhin2 | ||
| 1SRC VB, Koltsovo, Novosibirsk reg., 630559, Russia; 2Ural State Technical University, Yekaterinburg 620002, Russia | ||
| 98. | Resistance of Human Cytomegalovirus to Cyclopropavir Involves a Novel Mutation in UL97 | |
| Katherine Z. Borysko1, Brian G. Gentry1, Julie M. Breitenbach1, Jiri Zemlicka2, John C. Drach1 | ||
| 1Department of Biologic & Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI, USA; 2Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA | ||
| 99. | Synthesis and Activity of Vidarabine d-Amino Acid Prodrugs as Potential Pox Virus Agents | |
| Julie M. Breitenbach1, Wei Shen2, John Hilfinger2, John C. Drach1 | ||
| 1Department Biologic & Materials Sciences, University of Michigan, Ann Arbor, MI, USA; 2TSRL, Inc., Ann Arbor, MI, USA | ||
| 100. | Antiviral Activity of (−)-d-Carbocyclic Cytosine (Carbodine) Against Avian Influenza Virus (H5N1) | |
| C.K. Chu1,3, J. Rao1,3, C.W. Day2,3, D.L. Barnard2,3, D.F. Smee2,3 | ||
| 1University of Georgia, Athens, GA, USA; 2University of Georgia, Athens, GA, USA; 3Utah State University, Logan, UT, USA | ||
| 101. | Application of the Phosphoramidate Protide Approach to the Antiviral Drug Ribavirin | |
| Marco Derudas1, Christopher McGuigan1, Andrea Brancale1, Johan Neyts2, Jan Balzarini2 | ||
| 1Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; 2Rega Institute for Medical Research, Leuven, Belgium | ||
| 102. | Design, Synthesis and Biological Evaluation of Novel Acyclovir Protides | |
| Marco Derudas1, Christopher McGuigan1, Andrea Brancale1, Joachim Bugert2, Graciela Andrei3, Robert Snoeck3, Jan Balzarini3 | ||
| 1Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; 2School of Medicine, Department of Medical Microbiology, Cardiff University, Cardiff, United Kingdom; 3Rega Institute for Medical Research, Leuven, Belgium | ||
| 103. | Vidarabine Prodrugs as Potential Inhibitors of Adenosine Deaminase | |
| Brian G. Gentry1, Wei Shen2, Julie M. Breitenbach1, John Hilfinger2, John C. Drach1 | ||
| 1Department Biologic & Materials Sciences, University of Michigan, Ann Arbor, MI, USA; 2TSRL, Inc., Ann Arbor, MI, USA | ||
| 104. | Megaribavirin Aerosol for the Treatment of Influenza A Virus Infections in Mice | |
| Brian Gilbert1, Matthew McLeay2 | ||
| 1Baylor College of Medicine, Houston, TX, USA; 2MTM Research, LLC, Omaha, NE, USA | ||
| 105. | Therapy of Advanced Arenaviral Infection in Hamsters with T-705 | |
| Brian Gowen1, Min-Hui Wong1, Kie-Hoon Jung1, Kevin Bailey1, Yousuke Furuta2, John Morrey1 | ||
| 1Institute for Antiviral Research, Utah State University, Logan, UT, USA; 2Research Laboratories. Toyama Chemical Company Ltd., Toyama, Japan | ||
| 106. | Virucidal Activity of Extracts From Four Algae Species Against Herpes Simplex Virus | |
| Emma Harden1, Caroll Hartline1, Ruth Falshaw2, Susan Carnachan2, Earl Kern1, Mark Prichard1 | ||
| 1University of Alabama at Birmingham, Birmingham, AL, USA; 2Industrial Research Ltd., Lower Hutt, New Zealand | ||
| 107. | Luciferase-based Assay for Rapid Screening of Antivirals Against Human Cytomegalovirus | |
| Caroll Hartline, Earl Kern, Mark Prichard | ||
| University of Alabama at Birmingham, Birmingham, AL, USA | ||
| 108. | Carbocyclic l-Nucleoside Analogues as Potential Antiviral Agents | |
| Soenke Jessel, Chris Meier | ||
| Institute of Organic Chemistry, Department of Chemistry, Faculty of Science, University of Hamburg, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany | ||
| 109. | Immunoprophylaxis of Phleboviral Infection in Hamsters with Recombinant Eimeria Protozoan Surface Antigen | |
| Kie-Hoon Jung1, John W. Judge2, Min-Hui Wong1, Peter C. Melby3, Barnett Rosenberg2, John D. Morrey1, Brian B. Gowen1 | ||
| 1Institute for Antiviral Research, Utah State University, Logan, UT, USA; 2Barros Research Institute, Holt, MI, USA; 3Research Service, South Texas Veterans Health Care System and Department of Medicine, University of Texas Health Science Center, San Antonio, TX, USA | ||
| 110. | Novel Inhibitors of Orthopoxvirus Replication Target Vaccinia Virus P37 Envelope Protein | |
| Kathy A. Keith, Debra C. Quenelle, Shalisa Sanders, Robin C. Conley, Earl R. Kern, Mark N. Prichard | ||
| Department of Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA | ||
| 111. | Synthesis and Antiviral Activity of Various N4-Acyl Derivatives of Cidofovir and its 5-Azacytosine Counterpart, 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine | |
| Marcela Krecmerova1, Antonin Holy1, Graciela Andrei2, Lieve Naesens2, Johan Neyts2, Jan Balzarini2, Erik De Clercq2, Robert Snoeck2 | ||
| 1Gilead Sciences & IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium | ||
| 112. | Antiviral Effects of Sulfated Exopolysaccharide From the Marine Microalga Gyrodinium Impudicum Strain KG03 | |
| Chong-Kyo Lee1, Hae Soo Kim1, Ju Ryung Nam1, Myung-Jin Lee1, Joung-Han Yim2, Hong Kum Lee2 | ||
| 1Pharmacology Res, Ctr, Korea Research Institute of Chemical Technolog, Daejeon, Republic of Korea; 2Polar Biocenter, Korea Polar Research Institute, Incheon, Republic of Korea | ||
| 113. | Developing a Novel High-Throughput Screening Assay Against Bluetongue Virus | |
| Qianjun Li, Lynn Rasmussen, Clinton Maddox, E. Lucile | ||
| White Southern Research Institute, Birmingham, AL, USA | ||
| 114. | Antioxidant Properties of Oseltamivir—A Specific Na Inhibitor of Influenza Virus Infection Type A in Influenza Virus Infected Mice and in Some Model Systems | |
| Milka Mileva1, Angel S. Galabov2, Lora Simeonova2, Galina Gegova2 | ||
| 1Department of Medical Physics and Biophysics, Medical University, Sofia, Bulgaria; 2Department of Virology, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | ||
| 115. | Hit QSAR Analysis of Anti-Coxsackievirus B3 Activity of [(Biphenyloxy)Propyl]Isoxazole Derivatives | |
| E. Muratov1, V. Kuz’min1, A. Artemenko1, E. Varlamova1, V. Makarov2, O. Riabova2, P. Wutzler3, M. Schmidtke3 | ||
| 1A.V. Bogatsky Physical-Chemical Institute, Odessa, Ukraine; 2Research Center for Antibiotics, Moscow, Russia; 3Institute of Virology and Antiviral Therapy, F. Schiller University, Jena, Germany | ||
| 116. | Studying of Anti-Epstein-Barr Virus Activity of Amizon and their Derivative | |
| Nadiya Nesterova1, Svitlana Zagorodnya1, Valentina Danilenko2, Galina Baranova1, Anna Golovan1 | ||
| 1Institute of Microbiology and Virology, Kyiv, Ukraine; 2Institute of Pharmacology and Toxicology, Kyiv, Ukraine | ||
| 117. | Development of Resistance to Oxoglaucine in Poliovirus Type 1 (LSc-2ab) and the Six Coxsackie B Viruses | |
| Lubomira Nikolaeva-Glomb, Angel S. Galabov | ||
| The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | ||
| 118. | Efficacy of Therapeutic Intervention with an Oral Ether Lipid Analogue of Cidofovir (CMX001) in a Lethal Mousepox Model | |
| Scott Parker, Christina Oberle, Erin Touchette, R. Mark Buller | ||
| Saint Louis University Medical School, St. Louis, MO, USA | ||
| 119. | Synthesis of P-O-C-linked Foscarnet-Peptide Conjugates and Sensitive Methods to Detect the Released Drug in Biological Samples | |
| Chi V. Pham1, Boris A. Kashemirov1, Jorge Osuna1, Kanokkarn Saejueng1, John M. Hilfinger2, Charles E. McKenna1 | ||
| 1Department of Chemistry, University of Southern California, Los Angeles, CA, USA; 2TSRL, Inc., Ann Arbor, MI, USA | ||
| 120. | In Vivo Efficacy of CMX001 Against Herpes Simplex Virus Types 1 and 2 | |
| Debra Quenelle1, Deborah Collins1, Terri Rice1, George Painter2, Alice Robertson2, Earl Kern1 | ||
| 1The University of Alabama, School of Medicine, Birmingham, AL, USA; 2Chimerix, Inc., Durham, NC, USA | ||
| 121. | A Synthetic Strategy to Different Cyclopentenyl-Nucleosides | |
| Bastian Reichardt, Chris Meier | ||
| Institute of Organic Chemistry, Department of Chemistry, Faculty of Science, University of Hamburg, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany | ||
| 122. | Cyclopentenylcytosine (CPE-C) Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model | |
| Eric G. Romanowski, Kathleen A. Yates, Y. Jerold Gordon | ||
| The Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA, USA | ||
| 123. | Synthesis and Properties of Glycosyl-Functionalised Cyclosal-Pronucleotides | |
| Tilmann Schulz1, Jan Balzarini2, Chris Meier1 | ||
| 1Institute of Organic Chemistry, Department of Chemistry, Faculty of Science, University of Hamburg, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroederstraat 10, B-3000 Leuven, Belgium | ||
| 124. | Synthesis, Antiviral and Cytotoxic Activities of Some Novel 2, 3-Disubstituted Quinazolin-4(3H)-Ones | |
| Periyasamy Selvam1, Padamraj Rathore1, P Babu1, Leentje Persoons2, Erik De Clercq2 | ||
| 1Arulmigu Kalasalingam College of Pharmacy, Krishnankoil 626190, India; 2Arulmigu Kalasalingam College of Pharmacy, Krishnankoil 626190, India; 3Arulmigu Kalasalingam College of Pharmacy, Krishnankoil 626190, India; 4Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; 5Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium | ||
| 125. | Combined Anti-Influenza Virus Effects of a Plant Polyphenol-rich Extract and E-Aminocaproic Acid In Vitro and In Vivo | |
| Julia Serkedjieva, Ani Teodosieva | ||
| Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | ||
| 126. | Differential Pathogenesis of Cowpox Virus Intranasal Infections in Mice Induced by Low and High Inoculum Volumes, and Effects of Cidofovir Treatment | |
| Donald F. Smee1, Brian B. Gowen1, Miles K. Wandersee1, Min-Hui Wong1, Ramona T. Skirpstunas2, Thomas J. Baldwin2, Justin D. Hoopes2, Robert W. Sidwell1 | ||
| 1Institute for Antiviral Research, Utah State University, Logan, UT, USA; 2Utah Veterinary Diagnostic Laboratory, Utah State University, Logan, UT, USA | ||
| 127. | Herpes Simplex Virus Type 2 Exposed to Rigid Amphipathic Fusion Inhibitors (RAFIs) are not Infectious in a Mouse Vaginal Model | |
| Mireille St. Vincent1, Vladimir Korshun2, Alexey Ustinov2, Luis Schang1 | ||
| 1University of Alberta, Edmonton, AB, Canada; 2Russian Academy of Sciences, Moscow, Russia | ||
| 128. | Evaluation of C-5 Substituted Uracil Acyclic Phosphonates as Substrates or Inhibitors for DTMP and UMP-CMP Kinases and Potential Antipox Derivatives | |
| Dimitri Topalis1, Julie Broggi2, Julie A.C. Alexandre1, Ugo Pradère2, Vincent Roy2, Sabine Berteina-Raboin2, Luigi A. Agrofoglio2, Dominique Deville-Bonne1 | ||
| 1Laboratoire d’Enzymologie Moléculaire et Fonctionnelle, FRE2852 CNRS-Paris6, 4 Place Jussieu, 75252 Paris, France; 2Institut de Chimie Organique et Analytique, UMR CNRS 6005, FR2708, Université d’Orléans, 45067 Orléans, France | ||
| 129. | Effects of PTU-23, HBB, Ribavirin and Oxoglaucine on the Replication of Feline Calicivirus in CrFK Cells | |
| Julian Tumbarski1, Angel S. Galabov1 | ||
| 1The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria, 2The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | ||
| 130. | Increase of the Effect of Anti-Enteroviral Chemotherapy Used in Experimental Neurotropic Coxsackievirus B1 Infection in Newborn Mice When a Triple Combination of Antivirals is Administered in a Consecutive Treatment Course | |
| Ralitsa Vassileva-Pencheva, Angel S. Galabov | ||
| The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria | ||
| 131. | Prodrugs of Antiviral Nucleosides Cleavable by Dipeptidyl-Peptidase-IV (CD26) | |
| Sonsoles Velázquez1, Alberto Diez-Torrubia1, M. Teresa Peromingo1, Carlos García-Aparicio1, Jan Balzarini2, María-José Camarasa1 | ||
| 1Instituto de Química Médica (CSIC), Madrid, Spain; 2Rega Institute for Medical Research, KULeuven, Leuven, Belgium | ||
| 132. | Biochemical Evaluation of a New Potential Antiviral Drug HPMP-5-Azacytosine | |
| Ivan Votruba, Miroslav Hájek, Helena Kaiserová, Eva Tloušťová, Marcela Krečmerová, Antonín Holý | ||
| Institute of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic | ||
| 133. | A Microbicide Transmission and Sterilization Assay (MTSA) Defines the Effective Concentration of Topical HIV Microbicides Required to Suppress Virus Transmission | |
| Karen M. Watson, Christa E. Buckheit, Robert W. Buckheit Jr. | ||
| ImQuest BioSciences, Inc., Frederick, MD, USA | ||
| 134. | Stereospecificity, Substrate, and Inhibitory Properties of P-Borano Nucleoside Diphosphates for Creatine, Pyruvate, and NDP Kinases | |
| Charlotta Wennefors, Mikhail Dobrikov, Barbara-Ramsay Shaw | ||
| Duke University, Durham, NC, USA | ||
| 135. | Withdrawn | |
| 136. | Ring-expanded Nucleosides (RENs) Exhibit Potent ATP-dependent Helicase Activity of RNA Helicase Ddx3 with Little or no Toxicity in Ex Vivo Cell Culture or In Vivo in Mice | |
| Venkat Yedavalli2, Ning Zhang1, Hongyi Cai1, Kuan-Teh Jeang2, Ramachandra Hosmane1 | ||
| 1Laboratory for Drug Design & Synthesis, Department of Chemistry & Biochemistry, University of Maryland (UMBC), Baltimore, MD, USA; 2Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD, USA | ||